2'-O-methyl-modified phosphorothioate antisense oligonucleotides have reduced non-specific effects in vitro

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Therapeutics

Background:

• Antisense oligodeoxynucleotides (ODNs) demonstrate biological activity in cancer treatment.
• Phosphorothioate-modified ODNs (S-ODNs) and 2 -O-methyl-modified S-ODNs (Me-S-ODNs) are investigated for their antisense effects.

Purpose of the Study:

• To compare the antisense efficacy of S-ODNs and Me-S-ODNs targeting bcl-2 mRNA.
• To evaluate the biophysical properties and non-specific effects of these modified ODNs.

Main Methods:

• Comparison of Bcl-2 protein reduction in T24 cells after ODN transfection.
• Circular dichroism spectroscopy to analyze duplex formation and melting temperatures.
• Assays for binding to replication protein A, nuclease resistance, apoptosis induction (PARP cleavage), and RNase H degradation.

Main Results:

• Both S-ODNs and Me-S-ODNs effectively reduced Bcl-2 protein levels, comparable to G3139.
• Me-S-ODNs exhibited higher melting temperatures with RNA, reduced toxic growth inhibition, and less binding to replication protein A.
• Both ODN types were resistant to serum nucleases and did not induce apoptosis.

Conclusions:

• The addition of 2 -O-methyl groups to S-ODNs offers advantages including enhanced binding stability and reduced non-specific effects.
• Me-S-ODNs present a promising strategy for cancer therapy due to improved characteristics over standard S-ODNs.
• While Me-S-ODN hybrids are less sensitive to RNase H, their overall benefits outweigh this limitation.